WO2008148552A2 - Procédés et compositions apparentés à l'administration de l-carnitine - Google Patents

Procédés et compositions apparentés à l'administration de l-carnitine Download PDF

Info

Publication number
WO2008148552A2
WO2008148552A2 PCT/EP2008/004490 EP2008004490W WO2008148552A2 WO 2008148552 A2 WO2008148552 A2 WO 2008148552A2 EP 2008004490 W EP2008004490 W EP 2008004490W WO 2008148552 A2 WO2008148552 A2 WO 2008148552A2
Authority
WO
WIPO (PCT)
Prior art keywords
oil
carnitine
vitamin
water
animal
Prior art date
Application number
PCT/EP2008/004490
Other languages
English (en)
Other versions
WO2008148552A3 (fr
Inventor
Robert E. Musser
Jason C. Woodworth
Original Assignee
Lonza Inc
Lonza Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Inc, Lonza Ltd filed Critical Lonza Inc
Publication of WO2008148552A2 publication Critical patent/WO2008148552A2/fr
Publication of WO2008148552A3 publication Critical patent/WO2008148552A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins

Definitions

  • the present invention relates to compositions of L-carnitine and methods of using L-carnitine to improve the mortality and morbidity of animals experiencing periods of negative protein and/or energy balance.
  • the present invention further relates to the use of L-carnitine in combination with other supplemental or therapeutic compositions in order to facilitate improvement of the health status of unhealthy animals.
  • a major function of lipids as understood in modem nutrition is to serve as a substrate for production of metabolic energy. Mechanisms regulating the production of metabolic energy under a wide variety of physiological conditions are required for survival of the species, and have a critical role in the production of energy from long- chain fatty acids.
  • Carnitine facilitates the transport of fatty acids into the mitochondria.
  • Carnitine is a naturally occurring B vitamin-like compound found in humans and other mammals, aquatic life forms and birds.
  • carnitine was identified and synthesized long before the discovery of its nutritional role. Carnitine was first found in muscle extracts by two Russian scientists in 1905, identified as ⁇ -hydroxy- ⁇ - butyrobetaine, and named from the latin carnis, meaning flesh or meat. In the late 1940's, Fraenkel discovered that carnitine was a necessary substance for the mealworm Tenebrio molitor, and named it vitamin B n although it was later established that carnitine is not a vitamin for higher organisms. Early research literature also calls carnitine vitamin Bn. In 1959, Fritz found that carnitine stimulated the rate of fat burning (called "beta-oxidation").
  • Carnitine is chemically termed 3-hydroxy-4-N-trimethylamino butyric acid; it is similar to choline and a close cousin to amino acids. Unlike amino acids, carnitine is not used for protein synthesis. Carnitine is not a vitamin, because part of the animal requirement is fulfilled by biosynthesis. Carnitine, like many other biological molecules, comes in two forms: L-carnitine and D-carnitine. These isomers are mirror images of each other, much like the left hand is a mirror image of the right. Only the L-isomer is biologically active, however. The D-form is completely inactive, and may even inhibit the utilization of L-carnitine.
  • carnitine Whether supplied by the diet or from endogenous synthesis, carnitine is essential in the metabolism and movement of fatty acids within and between cells.
  • An enzyme, carnitine acyltransferase, has been found to be part of the mechanism for releasing CoA (co-enzyme A) and acyl-CoA.
  • the effect of carnitine on fatty acid metabolism seems to be limited to fatty acids with chain lengths greater than Cs. Palmitylcarnitine also stimulates fat synthesis in livers, so another vitamin role of carnitine may be in the regulation of lipogenesis.
  • Most organisms have the ability to produce their own carnitine. In 1980, Rebouche and Engel first demonstrated carnitine biosynthesis in humans.
  • the endogenous production of carnitine appears to occur mainly in the liver, and requires two amino acids, lysine and methionine, three vitamins, vitamin B 3 (niacin), vitamin Be and vitamin C (ascorbic acid), and iron.
  • Thmethyl-lysine is produced by methylation of lysine using a methyl group from methionine.
  • the trimethyl-lysine is converted to an aldehyde using PALP as a co-factor, which is oxidized to a butyrate by an NAD-linked dehydrogenase.
  • the butyrate is then hydroxylated by a ketoglutarate-ferrous ascorbate compound to form carnitine.
  • a method for treating animal disorders characterized by a negative protein or energy balance and limited feed intake includes preparing a mixture of water containing L-carnitine and a potable or ingestible acidifier; and delivering to an animal said water mixture as its water supply for free consumption.
  • a method for treating animal disorders characterized by a negative protein or energy balance and limited feed intake includes preparing first media having L-carnitine; preparing a second media having L-carnitine different from the first media; and delivering to an animal said first and second media having L-carnitine.
  • a method for treating animal disorders characterized by a negative protein or energy balance and limited feed intake includes preparing a mixture of water containing L-carnitine, an ingestible acidifier and animal feed.
  • a composition for treating animal disorders characterized by a negative protein or energy balance and little solid food intake includes L-carnitine; and one or more vitamins selected from the group consisting of pantothenic acid (Vitamin B 5 ), thiamin (Vitamin B 1 ), pyridoxine (Vitamin B 6 ), niacin
  • Vitamin B 3 folic acid (Vitamin B 9 ), riboflavin (Vitamin B 2 ), biotin (Vitamin B 7 ), vitamin Bi 2 , ascorbic acid (Vitamin C), choline, Vitamin A, Vitamin D, Vitamin E, Vitamin K and/or selenium.
  • such periods of negative protein and energy balance may be the result of a variety of health challenges, for example, porcine circovirus associated disease, post-weaning multisystemic wasting syndrome, circovirus, salmonellosis, transmissible gastroenteritis virus, ileitis, colibacillosis, dysentery, actinobacillus pleuropneumoniae, porcine respiratory disease complex (mycoplasma), hemolytic E. coli, hog cholera or influenza.
  • porcine respiratory disease complex mycoplasma
  • bovine respiratory syncytial virus infectious bovine rhinotracheitis, corona virus, bovine viral diarrhea or Johnes disease.
  • Such periods may be the result of, for example, equine infectious anemia. Such periods are commonly marked by an animal's reduction of or cessation of food intake. As a result, diets for such unhealthy animals need to be engineered to ensure that, even with a reduced or nonexistent feed intake, a sufficient amount of energy is available.
  • the present method addresses this by providing ways in which an effective amount of L-carnitine may be delivered.
  • L-carnitine may be provided as a supplement in the form of L-carnitine or an acceptable salt thereof, e.g., acetylated L-carnitine, L-tartrate carnitine, L-carnitine fumarate, L-carnitine chloride, L-carnitine magnesium citrate, L-carnitine acetyl-HCI, L- carnitine propionyl-HCI, and L-carnitine palmitoyl-HCI, in either a protected or unprotected form.
  • L-carnitine may be provided as a supplement in the form of L-carnitine or an acceptable salt thereof, e.g., acetylated L-carnitine, L-tartrate carnitine, L-carnitine fumarate, L-carnitine chloride, L-carnitine magnesium citrate, L-carnitine acetyl-HCI, L- carnitine propionyl-HCI, and L-carnitine palm
  • L-carnitine may be encapsulated in one or more materials capable of passing through the stomach without significantly dissolving and then dissolving in the small intestine so that L-carnitine is not absorbed until it reaches the small intestine.
  • gamma-butyrobetaine a precursor of L- carnitine
  • Various media for delivering L-carnitine may include drinking water, capsules, supplements, feed, injections (e.g., intramuscular, intraperitoneal, intravenous and subcutaneous), pastes, gels and tablets or any other media suitable for delivering L-carnitine to an animal or animal population.
  • injections e.g., intramuscular, intraperitoneal, intravenous and subcutaneous
  • pastes e.g., gels and tablets or any other media suitable for delivering L-carnitine to an animal or animal population.
  • L-carnitine is provided in an animal's drinking water. Previously, providing L-carnitine in water was disfavored because it led to bacterial growth in the water. However, it has been determined that combining a suitable potable acidifier with L-carnitine in the water prevents bacterial flourishing because the acidifier serves as an antibacterial agent. Accordingly, for example, L-carnitine may be combined with a suitable amount of an acidifier and introduced into an unhealthy animal's water supply. [022] L-carnitine ingested via the water supply may, as discussed above, facilitate improvement of an animal's body energy reserves during times of limited or restricted feed intake, thereby improving feed conversion and average daily gain.
  • L-carnitine may be provided to each animal per day. Accordingly, when providing swine with the L-carnitine in drinking water, the amount of L-carnitine in the water supply may range from 0.000013 to 2.116 mg L-carnitine per ml of water. In another implementation about 0.01 to 2 grams of L-carnitine may be provided to an animal per day, which equates to from 0.00132 to 1.0582 mg L-carnitine per ml of water.
  • L-carnitine may be provided in the water in an amount sufficient to deliver to an animal 0.001 to 4 grams per day of L-carnitine. In one embodiment where water consumption falls in the range from half to full normal amount, L-carnitine may be provided in the water in an amount sufficient to deliver to an animal 0.01 to 2 grams per day of L-carnitine.
  • L-carnitine may be provided in the water in an amount sufficient to deliver to an animal 0.5 grams per day of L-carnitine.
  • the amount of acidifier added to the water supply may vary depending on the acidifier type.
  • Various potable or ingestible acidifiers may be used in accordance with the present invention and may include, for example, citric acid, formic acid, butyric acid, lactic acid, phosphoric acid and/or propionic acid.
  • the amount of acidifier used is determined by identifying the amount of acidifier required to prevent bacteria from degrading L-carnitine and from building bacterial populations that may foul water lines.
  • the mixture of L-carnitine to citric acid is about 80 parts L-carnitine to about 20 parts citric acid, and may be provided as a premix for addition to water supplies.
  • citric acid in an amount of 120 mg/ml of water may be included in the L-carnitine supplemented water supply of animal populations experiencing health disorders characterized by increased body protein catabolism and/or negative energy balance.
  • citric acid in a range of 50-300 mg/ml of water may be included in the L-carnitine supplemented water supply.
  • the pH of the water, L-carnitine and acid mixture may vary, for example, depending on the acidifier(s) selected and on the quality of the water supply, e.g., hard water generally has a starting pH of 8.0.
  • the pH may be adjusted so that it falls below a pH of 7.0 such that an acidic environment unfriendly to bacterial growth is created. It should be understood that other acids have known antibacterial and/or bacteriocidal effectiveness at a different pH than citric acid, and the pH of the mixture may be adjusted according to the selected acidifier.
  • the above-mentioned embodiment may provide advantages over supplementing L-carnitine in the feed of animal populations experiencing health disorders.
  • L-carnitine in water supplies may ensure that the unhealthy animal population, which in most instances continues to drink water, still receives the intended amount of L-carnitine. Because it is believed that L-carnitine supplements may improve the health status of such animal populations, its consistent delivery via the water supply may increase the probability that the animal populations will have improved mortality and morbidity.
  • L-carnitine and acidifier composition may also be useful when delivering L-carnitine to health challenged animal populations via pastes and gels. Due to the aqueous environment present in many pastes and gels, L-carnitine introduced into such media creates a suitable environment for bacterial growth.
  • L-carnitine may be provided in food supplies of animal populations experiencing health disorders, but still consuming animal feed.
  • an amount of L-carnitine used to supplement daily intake may be from 0.0001 to 4.0 grams (0.1 mg to 4000 mg) of L-carnitine, and the amount added to each kg. of feed depends on the food intake per animal per day.
  • the feed may be corn, oats or other feeds traditionally fed to various species.
  • L-carnitine and an acidifier composition may be provided in wet feed supplies or water/feed mixtures of an animal population. Due to the wet environment in the feed, providing an acidifier with L-carnitine may provide the wet media with antibacterial properties that may allow for the safe delivery of L-carnitine to the animal population.
  • L-carnitine may be provided as a supplement to health challenged animal populations and delivered in pill or capsule form.
  • L-carnitine may be a component of a base mix, a premix, a concentrate, in a vitamin micromineral (trace mineral) and/or macromineral mix fed to health challenged animal populations.
  • L-carnitine may be provided via injection to health challenged animal populations.
  • Additional Ingredients and Compositions may be used alone or combined with a feed supplement.
  • L-carnitine may be provided with vitamins and minerals such as pantothenic acid (Vitamin B 5 ), thiamin (Vitamin Bi), pyridoxine (Vitamin B 6 ), niacin (Vitamin B 3 ), folic acid (Vitamin Bg), riboflavin (Vitamin B 2 ), biotin (Vitamin B 7 ), vitamin Bi 2 , ascorbic acid (Vitamin C), choline, Vitamin A, Vitamin D, Vitamin E, Vitamin K, iron, selenium, cobalt, chromium, copper, iodine, manganese, zinc, and/or molybdenum.
  • vitamins and minerals such as pantothenic acid (Vitamin B 5 ), thiamin (Vitamin Bi), pyridoxine (Vit
  • L- carnitine with one or more vitamins or minerals may provide greater benefits than L- carnitine alone, because when L-carnitine causes metabolic processes to increase, vitamins and minerals in the body are consumed and need replenishing to meet the metabolic need.
  • the consumed vitamins and/or minerals may be replenished and/or may be provided at therapeutic amounts.
  • any of the vitamins may be used alone or in combination in an amount between 0.2-2 mg/day or 50-500 IU/day.
  • vitamins and minerals combined with L-carnitine may be provided to each head of swine in a range from the table listed below in Table 1.
  • the range of vitamins and minerals provided may fall in the low to middle range of values provided in Table 1.
  • piglets may be provided an amount of vitamins and minerals falling near the low range
  • full-grown swine may be provided the same vitamins and minerals in an amount falling near the middle range.
  • the vitamins and minerals may be provided in an amount falling between the low and high range.
  • Further components or other feed supplements may in addition or alternatively be added to an L-carnitine supplemented media.
  • therapeutic agents for treating a particular disorder in the animal population may be provided.
  • Tylan® tylosin antibiotic
  • Denaguard® tiamulin
  • neomycin penicillin or other substances for use as a therapeutic management tool
  • Tylan® tylosin antibiotic
  • Denaguard® tiamulin
  • neomycin penicillin or other substances for use as a therapeutic management tool
  • specialty proteins that deliver antibody-type products, mannon oligosaccharides, fructooligosaccharides and/or arabinogalactan may be delivered at 0.25-5 grams per head per day and/or sodium butyrate may be included in an L-carnitine supplemented media in order to prevent the animal populations from experiencing further health disorders.
  • essential oils may include anise, cardamom, chamomile, cinnamon, citronella, clove, cumin, eucalyptus, fennel seed, fenugreek, geranium, ginger, henna, juniper berry, lavender, lemon and other citrus extracts, mentha arvensis, menthol (mint and/or peppermint), onion, oregano, orris, rosehip, rosemary, rosewood, sage, sandalwood, terragon, tea tree, thyme, thymol and/or yarrow.
  • One or more of the aforementioned essential oils may provide antibacterial or bacteriocidal properties and may be provided in a range of 10-200 ppm, or at 50 ppm, for example. Further, one or more of the aforementioned essential oils may provide flavoring to water or feed, making the delivery material more palatable and/or desirable for an animal.
  • the aforementioned additional ingredients are used in their water-soluble forms or may be made water soluble, along with L-carnitine, for example using a coating or an encapsulation technology.
  • compositions that may be prepared for treatment of the condition of negative protein or energy balance are the following: [039] Embodiment 1 : L-carnitine, potable acidifier, Vitamin E and selenium
  • L-carnitine may be provided in an amount between 0.000013 and 2.116 mg per ml of water, a potable acidifier provided in an amount between 0.001 and 6.00 mg per ml of water, Vitamin E provided in an amount between 0.00026 and 0.244 IU per ml of water, and selenium provided in an amount between 0.000026 and 0.00106 mg per ml of water.
  • L-carnitine in an amount between 0.06605 and 2.626 mg per ml of water, an acidifier in an amount between 0.05 and 3.00 mg per ml of water, Vitamin E in an amount between 0.013 and 0.053 IU per ml of water, and selenium in an amount between 0.00026 and 0.00106 mg per ml of water.
  • Embodiment 2 L-carnitine, potable acidifier, Vitamin E, selenium and essential oils
  • L-carnitine may be provided in an amount between 0.000013 and 2.116 mg per ml of water, a potable acidifier provided in an amount between 0.001 and 6.00 mg per ml of water, Vitamin E provided in an amount between 0.00026 and 0.244 IU per ml of water, selenium provided in an amount between 0.000026 and 0.00106 mg per ml of water, and essential oils provided in an amount between 0.00132 and 0.21164 mg per ml of water.
  • L-carnitine in an amount between 0.06605 and 2.626 mg per ml of water, an acidifier in an amount between 0.05 and 3.00 mg per ml of water, Vitamin E in an amount between 0.013 and 0.053 IU per ml of water, selenium in an amount between 0.00026 and 0.00106 mg per ml of water, and essential oils in an amount between 0.0132 and 0.053 mg per ml of water.
  • Embodiment 3 L-carnitine, potable acidifier, Vitamin E, selenium, essential oils and arabinogalactan
  • L-carnitine may be provided in an amount between 0.000013 and 2.116 mg per ml of water, a potable acidifier provided in an amount between 0.001 and 6.00 mg per ml of water, Vitamin E provided in an amount between 0.00026 and 0.244 IU per ml of water, selenium provided in an amount between 0.000026 and 0.00106 mg per ml of water, essential oils provided in an amount between 0.00132 and 0.21164 mg per ml of water, and arabinogalactan provided in an amount between 0.000032 and 0.00265 mg per ml of water.
  • L-carnitine in an amount between 0.06605 and 2.626 mg per ml of water, an acidifier in an amount between 0.05 and 3.00 mg per ml of water, Vitamin E in an amount between 0.013 and 0.053 IU per ml of water, selenium in an amount between 0.00026 and 0.00106 mg per ml of water, essential oils in an amount between 0.0132 and 0.053 mg per ml of water, and arabinogalactan in an amount between 0.00026 and 0.00106 mg per ml.
  • Embodiment 4 L-carnitine, potable acidifier, Vitamin E, selenium, essential oils, arabinogalactan and Vitamin C
  • L-carnitine may be provided in an amount between 0.000013 and 2.116 mg per ml of water, a potable acidifier provided in an amount between 0.001 and 6.00 mg per ml of water, Vitamin E provided in an amount between 0.00026 and 0.244 IU per ml of water, selenium provided in an amount between 0.000026 and 0.00106 mg per ml of water, essential oils are provided in an amount between 0.00132 and 0.21164 mg per ml of water, arabinogalactan provided in an amount between 0.000032 and 0.00265 mg per ml of water, and Vitamin C provided in an amount between 0.00132 and 0.26455 mg per ml of water.
  • L-carnitine in an amount between 0.06605 and 2.626 mg per ml of water, an acidifier in an amount between 0.05 and 3.00 mg per ml of water, Vitamin E in an amount between 0.013 and 0.053 IU per ml of water, selenium in an amount between 0.00026 and 0.00106 mg per ml of water, essential oils in an amount between 0.0132 and 0.053 mg per ml of water, arabinogalactan in an amount between 0.00026 and 0.00106 mg per ml, and Vitamin C in an amount between 0.06605 and 0.26455 mg per ml of water.
  • Such mixtures may preferably be handled at micropremix facilities in order to accurately measure the supplemented materials. Mixing facilities that meet good manufacturing practices (GMPs), e.g., for blending and manufacturing, in general are preferred.
  • GMPs good manufacturing practices
  • compositions described may be used for the manufacture of a medicament for therapeutic application to animals suffering from a period of negative protein or energy balance. Accordingly, the invention also includes use of a fatty acid metabolism increasing effective amount of L-carnitine in the manufacture of a diet or medicament for oral administration, the diet or medicant comprising a bacteria growth preventing or bacteriocidal amount of an ingestible acidifier, for the treatment of periods of negative protein or energy balance in animals.
  • the ingestible acidifier is selected from the group consisting of citric acid, formic acid, butyric acid, lactic acid, phosphoric acid, propionic acid, and any combination of the foregoing acids. From 0.001 to 4 grams of L-carnitine may be administered per day; from 0.01 to 2 grams of L-carnitine may be administered per day; or 0.5 grams of L-carnitine may be administered per day.
  • Vitamin E and selenium may be used in combination with L-carnitine and a potable acidifier, Vitamin E provided in an amount between 0.00026 and 0.244 IU per ml of water and selenium provided in an amount between 0.000026 and 0.00106 mg per ml of water.
  • Other substances may be included with the above-described mixture, and may include those described in Embodiments 2-4 above.
  • the amount of L-carnitine, potable acidifier, Vitamin E, selenium and other substances may vary, and may be present in ranges such as those described in Embodiments 1-4 above.
  • a fatty acid metabolism increasing effective amount of L- carnitine may be combined with vitamins and minerals in the manufacture of a diet or medicament for oral administration for the treatment of periods of negative protein or energy balance in animals.
  • essential oils may be in addition or alternatively combined with L-carnitine in order to achieve increased fatty acid metabolism.
  • the fatty acid metabolism increasing effective amount of L-carnitine with an ingestible acidifier may treat porcine circovirus associated disease, post-weaning multisystemic wasting syndrome, circovirus, salmonellosis, transmissible gastroenteritis virus, ileitis, colibacillosis, dysentery, actinobacillus pleuropneumoniae, porcine respiratory disease complex (mycoplasma), hemolytic E. coli, hog cholera and/or influenza, bovine respiratory syncytial virus, infectious bovine rhinotracheitis, corona virus, bovine viral diarrhea or Johnes disease, and equine infectious anemia.
  • Treatment Modes Treatment Modes.
  • L-carnitine used alone or in combination with the above-mentioned substances may be provided as a supplement to animal populations having compromised health daily for a period of 1 to 45 days, for a duration of about 1 day to 28 days, or for a duration of 7 to 14 days. L-carnitine may also be used alone or in combination for a duration of greater than 45 days. Alternatively, L-carnitine may be provided intermittently over a period of time, e.g., every 2, 3, 4, 5 or 6 days, once a week, twice a month, once a month, or once every 45 days.
  • Treatment modes may also have a variable time frame. For example, a treatment period may begin once a period of negative energy or protein imbalance is detected; and upon an animal or animal population positively responding to treatment with L-carnitine, the treatment period may reach an end point.
  • Positive responses in an animal or animal population may include the animal or animal population ceasing weight loss, beginning weight gain, eating feed, eating a targeted amount of feed, or having an appearance or behavior indicative of adequate health.
  • L-carnitine treatment may be modified upon identifying such health markers.
  • L-carnitine may be provided to a population in various forms during a treatment period.
  • L-carnitine may be provided in an animal population's water supply for a first portion of a treatment period and then may be provided in feed alone (e.g., mixed with corn, oats or other feeds traditionally provided to various species) or in combination with L-carnitine supplemented water.
  • a preferred amount of L-carnitine may be provided in the water supply, while additional L-carnitine may be provided in animal feed (e.g., mixed with corn, oats or other feeds traditionally provided to various species). This may ensure that the population is receiving at least an intended amount of L-carnitine, even when some animals ingest only water and no feed.
  • each of L-carnitine and other therapeutic or metabolic substances may be delivered to an animal population via separate media.
  • L-carnitine may be provided to an animal population via its water supply, and vitamin supplements may be provided in tablet form or may be injected. This may be useful in situations where vitamins or other substances do not easily flow or disperse in water supplies.
  • the amount of L-carnitine provided to an animal population may vary during a treatment period. For example, more or less L- carnitine may be provided to a population at the beginning of a treatment regimen compared to the end of the treatment period.
  • L-carnitine may be provided simultaneously via two or more media. For example, L-carnitine supplemented water and topical gel may be introduced in an animal population.
  • L-carnitine may be provided to an animal population regardless of their current health status. L-carnitine may be provided in a maintenance dose, for example. This may be useful for animal populations in general because it is typical for at least some animals in a large production population to have some sort of health challenge that could benefit from L-carnitine supplementation.
  • an effective amount L-carnitine required for an animal may be dependent inter alia on its ailment, age, sex, species, breed, and feed composition. As a result, if individual water or feed intake can be provided, L-carnitine may be provided among animals in the same population in different amounts depending a particular animal's makeup. However, it should be noted that delivery of L-carnitine in a common water supply for healthy and health challenged animals, is acceptable, as there appears to be no ill effect to providing healthy animals L-carnitine in the amounts that are helpful for health challenged animals.
  • the response of an L-carnitine supplemented diet in animals within a population may vary due to their makeup. Accordingly, growth rate, feed conversion, and carcass composition may differ within an animal population, even if each animal is receiving the same supplemental amount of L-carnitine.
  • the methods of the present invention can be practiced with respect to many kinds of health challenged animals having a metabolism that involves L-carnitine and who may suffer from periods of negative protein and/or energy balance, including non-ruminants, ruminants, avian, and aquaculture.
  • Meat, milk and egg producing animals livestock in general, production livestock animals, companion animal, i.e., horses, cats, dogs, rabbits, may all be provided with L-carnitine supplemented media. It is further understood that the methods are practiced according to one embodiment, with respect to swine. In a further alternative, the methods are practiced with livestock or any known animal.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des compositions pour traiter des troubles chez les animaux caractérisés par un équilibre de protéine ou d'énergie négatif et une absorption alimentaire limitée, lesquels procédés et compositions comprennent la fourniture d'un mélange préparé à partir d'un mélange d'eau contenant de la L-carnitine et d'un acidifiant potable, et l'administration à un animal du mélange aqueux en tant qu'alimentation en eau pour une consommation libre. Un autre procédé de traitement chez l'animal met en jeu la préparation de premier et second milieux ayant de la L-carnitine, le second milieu étant différent du premier milieu, et l'administration à un animal des premier et second milieux ayant de la L-carnitine. De tels milieux peuvent comprendre de l'eau potable, des capsules, des compléments, des aliments, des injections, par exemple, intramusculaires, intrapéritonéales, intraveineuses et sous-cutanées, des pâtes, des gels et des comprimés ou tout autre milieu approprié pour une administration de L-carnitine à un animal ou une population d'animaux.
PCT/EP2008/004490 2007-06-05 2008-06-05 Procédés et compositions apparentés à l'administration de l-carnitine WO2008148552A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94206607P 2007-06-05 2007-06-05
US60/942,066 2007-06-05

Publications (2)

Publication Number Publication Date
WO2008148552A2 true WO2008148552A2 (fr) 2008-12-11
WO2008148552A3 WO2008148552A3 (fr) 2009-02-19

Family

ID=39877771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004490 WO2008148552A2 (fr) 2007-06-05 2008-06-05 Procédés et compositions apparentés à l'administration de l-carnitine

Country Status (1)

Country Link
WO (1) WO2008148552A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153572A1 (fr) * 2008-06-20 2009-12-23 Aberystwyth University Matériels biologiques et leurs utilisations
CN102370098A (zh) * 2011-09-24 2012-03-14 长治市雄丰清真养殖屠宰有限公司 预防牛传染性鼻气管炎的饲料组合物
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
CN102579668A (zh) * 2011-12-31 2012-07-18 邵常雪 一种临床护理用治疗小儿细菌性痢疾的中药灌肠剂
CN104800794A (zh) * 2015-04-22 2015-07-29 格特生物制药（天津）有限公司 一种治疗鸽沙门氏菌病的中药组合物及其制备方法
CN107744063A (zh) * 2017-10-20 2018-03-02 浙江耀飞生物科技有限公司 一种耐高温型复合饲料酸化剂及制备方法
WO2020092243A1 (fr) * 2018-10-29 2020-05-07 Lonza Inc. Procédé et composition pour augmenter la biodisponibilité de la carnitine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
US5192804A (en) * 1991-03-22 1993-03-09 Lonza Inc. Carnitine-supplemented diet for starter pigs
US20040156882A1 (en) * 2002-10-23 2004-08-12 Davenport David F. Method and composition for feeding mammals
US20070042020A1 (en) * 2003-10-30 2007-02-22 Howard James R Composition for the treatment of dysfunctional energy metabolism syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
US5192804A (en) * 1991-03-22 1993-03-09 Lonza Inc. Carnitine-supplemented diet for starter pigs
US20040156882A1 (en) * 2002-10-23 2004-08-12 Davenport David F. Method and composition for feeding mammals
US20070042020A1 (en) * 2003-10-30 2007-02-22 Howard James R Composition for the treatment of dysfunctional energy metabolism syndrome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JANSSENS G P J; HESTA MYRIAM; DE WILDE R O M: "The effect of L-carnitine on body weight, body composition and nutrient intake in adult pigeons (Columba livia domestica)" ARCHIV FÜR GEFLÜGELKUNDE, vol. 64, no. 1, January 2000 (2000-01), pages 29-33, XP008098425 *
WPI WORLD PATENT INFORMATION DERWENT, DERWENT, GB, vol. 1992, no. 33, 23 September 1991 (1991-09-23), XP002163196 *
WPI WORLD PATENT INFORMATION DERWENT, DERWENT, GB, vol. 1993, no. 25, 29 June 1992 (1992-06-29), XP002163192 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153572A1 (fr) * 2008-06-20 2009-12-23 Aberystwyth University Matériels biologiques et leurs utilisations
AU2009261747B2 (en) * 2008-06-20 2014-04-03 Aberystwyth University Biological materials and uses thereof
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
CN102370098A (zh) * 2011-09-24 2012-03-14 长治市雄丰清真养殖屠宰有限公司 预防牛传染性鼻气管炎的饲料组合物
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8545896B2 (en) 2011-09-29 2013-10-01 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
CN102579668A (zh) * 2011-12-31 2012-07-18 邵常雪 一种临床护理用治疗小儿细菌性痢疾的中药灌肠剂
CN104800794A (zh) * 2015-04-22 2015-07-29 格特生物制药（天津）有限公司 一种治疗鸽沙门氏菌病的中药组合物及其制备方法
CN107744063A (zh) * 2017-10-20 2018-03-02 浙江耀飞生物科技有限公司 一种耐高温型复合饲料酸化剂及制备方法
WO2020092243A1 (fr) * 2018-10-29 2020-05-07 Lonza Inc. Procédé et composition pour augmenter la biodisponibilité de la carnitine

Also Published As

Publication number Publication date
WO2008148552A3 (fr) 2009-02-19

Similar Documents

Publication Publication Date Title
US5030657A (en) L-carnitine supplemented catfish diet
KR101230977B1 (ko) 동물 식품 첨가제로서 이용되는 구아니디노 아세트산
WO2008148552A2 (fr) Procédés et compositions apparentés à l'administration de l-carnitine
US20030194423A1 (en) Composition for enhancing nutritional content of food
JP2012176949A (ja) ビタミンｄ化合物の使用
US5360823A (en) Anionic salt formulation for milk fever
TW200800038A (en) Use of 25-hydroxy vitamin D3 to improve vitality of animals
NL1021963C1 (nl) Antimicrobiele samenstelling voor dieren.
Emara Comparative Effects of Nano-Selenium and Sodium Selenite Supplementation on Blood Biochemical Changes in Relation to Growth Performance of Growing New Zealand White Rabbits.
CN106578529A (zh) 一种改善仔猪生产性能、肠道健康和抗氧化性能的组合物及其制备方法
Nagar et al. Influence of dietary supplementation of Shatavari (Asparagus racemosus) and Ashwagandha (Withania somnifera) root powder on feed intake and body weight performance in caged broilers
US20140228329A1 (en) Use of 25-hydroxy vitamin d3 to promote phosphorous utilisation in ruminants
JPH03500243A (ja) ２‐デオキシ‐ｄ‐ヘキソースの経口投与による産肉性動物の飼料要求率の改良方法
Chen et al. Responses of broilers at moderate or high temperatures to dietary arginine: lysine ratio and source of supplemental methionine activity
HU187467B (en) Method for producing preparation suitable for preventing health deterioration of alimentary origin promoting the utilization of fodder of animals
US9358238B2 (en) Method of enhancing the performance of broiler chickens
Abou–Ashour et al. Effect of dietary citric, acetic acids or their mixture on broiler chicks performance, carcass characteristics and some intestinal histomorphological parameters
RU2425674C2 (ru) Комплексный фармацевтический препарат
EP1691626B1 (fr) Complement nutritionnel pour l'homme et l'animal. et utilisation
Elmali et al. Effects of supplementation with different amounts of malic acid to Tuj lambs diets on fattening performance, rumen parameters and digestibility
RU2227027C1 (ru) Способ лечения гепатодистрофии у поросят-отъемышей
WO2022040590A1 (fr) Produits et procédés pour augmenter la production d'oxyde nitrique et gérer un stress oxydatif
US20230363417A1 (en) Products and methods for increasing nitric oxide production and managing oxidative stress
WO2020243975A1 (fr) Utilisation d'une composition nutraceutique dans l'alimentation animale
NZ617576B2 (en) Use of 25-hydroxy vitamin d3 to promote phosphorous utilisation in ruminants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08784507

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08784507

Country of ref document: EP

Kind code of ref document: A2